EdgeMarket › What Opaleye Management Inc. reported owning
What Opaleye Management Inc. reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
759.2MPositions
54Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| HROW HARROW, INC. | 99.9M | 13.2% | 2.8M | 40.95 | +7.1% |
| LQDA Liquidia Corp | 88.8M | 11.7% | 2.5M | 68.62 | +150.9% |
| ETON Eton Pharmaceuticals, Inc. | 70.6M | 9.3% | 2.9M | 63.47 | +283.5% |
| SLGL Sol-Gel Technologies Ltd. | 39.6M | 5.2% | 500.0K | 77.73 | +322.4% |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 35.3M | 4.7% | 123.0K | 110.00 | +11.4% |
| APGE Apogee Therapeutics, Inc. | 32.8M | 4.3% | 390.0K | 134.75 | +274.1% |
| IRON Disc Medicine, Inc. | 26.9M | 3.5% | 421.0K | 79.81 | +35.9% |
| URGN UroGen Pharma Ltd. | 25.7M | 3.4% | 1.4M | 46.86 | +142.7% |
| CBIO CRESCENT BIOPHARMA, INC. | 24.1M | 3.2% | 1.3M | 17.15 | +24.3% |
| STOK Stoke Therapeutics, Inc. | 22.8M | 3.0% | 700.0K | 32.29 | +67.1% |
| CATX Perspective Therapeutics, Inc. | 19.5M | 2.6% | 4.7M | 3.30 | -2.4% |
| RZLT Rezolute, Inc. | 19.2M | 2.5% | 6.3M | 5.09 | -23.6% |
| MGTX MeiraGTx Holdings plc | 18.4M | 2.4% | 2.1M | 14.34 | +89.7% |
| TGTX TG THERAPEUTICS, INC. | 17.8M | 2.3% | 535.0K | 54.27 | +91.7% |
| SNWV SANUWAVE Health, Inc. | 17.0M | 2.2% | 981.3K | 4.61 | -88.3% |
| EWTX Edgewise Therapeutics, Inc. | 15.8M | 2.1% | 500.0K | 44.18 | +219.2% |
| ACOG Alpha Cognition Inc. | 14.1M | 1.9% | 2.6M | 9.75 | +22.0% |
| ANNX Annexon, Inc. | 12.9M | 1.7% | 2.3M | 5.07 | +136.9% |
| ALMS ALUMIS INC. | 12.1M | 1.6% | 550.0K | 24.17 | +448.1% |
| CDXS CODEXIS, INC. | 11.1M | 1.5% | 6.8M | 1.67 | -40.8% |
| PTGX Protagonist Therapeutics, Inc | 10.5M | 1.4% | 100.0K | 154.32 | +174.4% |
| RVMD Revolution Medicines, Inc. | 9.7M | 1.3% | 100.0K | 209.46 | +479.3% |
| unmapped CUSIP 98419J206 | 9.4M | 1.2% | 300.0K | — | — |
| QTTB Q32 Bio Inc. | 8.1M | 1.1% | 1.3M | 15.97 | +763.2% |
| MBX MBX Biosciences, Inc. | 7.8M | 1.0% | 260.0K | 66.33 | +386.6% |
| RLMD RELMADA THERAPEUTICS, INC. | 6.5M | 0.9% | 935.0K | 4.63 | +655.9% |
| CGON CG Oncology, Inc. | 6.4M | 0.8% | 94.8K | 79.81 | +212.6% |
| JBIO Jade Biosciences, Inc. | 6.0M | 0.8% | 427.6K | 21.34 | +211.5% |
| OCUL OCULAR THERAPEUTIX, INC | 5.1M | 0.7% | 600.0K | 11.08 | -7.4% |
| unmapped CUSIP 04546C304 | 5.1M | 0.7% | 265.7K | — | — |
| EDIT Editas Medicine, Inc. | 4.8M | 0.6% | 1.9M | 3.11 | +16.5% |
| STRO SUTRO BIOPHARMA, INC. | 4.7M | 0.6% | 190.7K | 21.04 | +143.4% |
| DERM Journey Medical Corp | 4.5M | 0.6% | 960.0K | 7.75 | +9.6% |
| VYGR Voyager Therapeutics, Inc. | 4.4M | 0.6% | 1.1M | 3.39 | +1.2% |
| TRVI Trevi Therapeutics, Inc. | 4.1M | 0.5% | 345.1K | 17.96 | +142.0% |
| TECX Tectonic Therapeutic, Inc. | 3.8M | 0.5% | 123.0K | 37.63 | +56.3% |
| CABA Cabaletta Bio, Inc. | 3.7M | 0.5% | 1.4M | 3.13 | +98.1% |
| BDSX BIODESIX INC | 3.5M | 0.5% | 238.0K | 26.63 | +224.7% |
| RCKT ROCKET PHARMACEUTICALS, INC. | 3.4M | 0.5% | 955.0K | 3.51 | -6.4% |
| ZNTL Zentalis Pharmaceuticals, Inc. | 3.3M | 0.4% | 1.4M | 3.83 | +133.2% |
| NTLA Intellia Therapeutics, Inc. | 3.1M | 0.4% | 245.0K | 12.84 | +25.8% |
| FBIO Fortress Biotech, Inc. | 2.9M | 0.4% | 1.0M | 2.87 | +40.0% |
| IRD Opus Genetics, Inc. | 2.3M | 0.3% | 1.1M | 4.05 | +249.1% |
| RIGL RIGEL PHARMACEUTICALS INC | 1.9M | 0.2% | 70.0K | 45.89 | +11.0% |
| AVIR Atea Pharmaceuticals, Inc. | 1.7M | 0.2% | 322.6K | 5.43 | +55.1% |
| LYEL Lyell Immunopharma, Inc. | 1.6M | 0.2% | 79.1K | 15.53 | +45.8% |
| ENTA ENANTA PHARMACEUTICALS INC | 1.6M | 0.2% | 125.0K | 13.47 | +52.7% |
| NXTC NextCure, Inc. | 1.5M | 0.2% | 141.2K | 6.29 | +22.6% |
| FDMT 4D Molecular Therapeutics, Inc. | 1.0M | 0.1% | 112.3K | 15.83 | +131.1% |
| unmapped CUSIP 46489V902 | 834.0K | 0.1% | 200.0K | — | — |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →